博济医药
(300404)
| 流通市值：30.43亿 | | | 总市值：41.13亿 |
| 流通股本：2.85亿 | | | 总股本：3.86亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 220,156,809.56 | 868,644,086.02 | 584,317,656.85 | 361,448,457 |
| 营业收入 | 220,156,809.56 | 868,644,086.02 | 584,317,656.85 | 361,448,457 |
| 二、营业总成本 | 196,959,149.06 | 822,637,193.21 | 554,800,483.18 | 339,017,207.06 |
| 营业成本 | 157,520,877.07 | 633,027,989.14 | 415,847,176.08 | 250,680,746.54 |
| 税金及附加 | 1,581,829.48 | 7,569,155.46 | 5,374,166.84 | 3,362,885.66 |
| 销售费用 | 11,910,238.41 | 56,883,114.31 | 41,415,253.66 | 25,595,831.69 |
| 管理费用 | 13,828,815.66 | 66,675,417.4 | 52,257,776.08 | 35,509,416.35 |
| 研发费用 | 11,901,099.26 | 57,497,869.16 | 38,925,834.02 | 23,199,684.18 |
| 财务费用 | 216,289.18 | 983,647.74 | 980,276.5 | 668,642.64 |
| 其中:利息费用 | 310,285.3 | 1,675,585.04 | 1,249,884.25 | 901,597.45 |
| 其中:利息收入 | 79,933.52 | 830,750.02 | 413,797.57 | 316,426.73 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 839,242.57 | 1,482,850.18 | 1,312,070.54 | 914,273.99 |
| 加:投资收益 | 443,192.39 | 837,663.49 | 422,611.89 | 301,173.62 |
| 资产减值损失(新) | -162,731.61 | -10,211,557.18 | -6,434,398.97 | -4,518,309.7 |
| 信用减值损失(新) | -5,905,506.67 | -19,896,365.19 | -13,636,718.7 | -8,848,206.87 |
| 其他收益 | 1,273,070.46 | 13,063,692.05 | 7,428,366.12 | 3,732,202.32 |
| 四、营业利润 | 19,684,927.64 | 31,283,176.16 | 18,609,104.55 | 14,012,383.3 |
| 加:营业外收入 | 2,527.52 | 11,722.18 | 2,224.58 | 1,932.3 |
| 减:营业外支出 | 7,215.44 | 1,238,227.78 | 280,696.32 | 160,392.36 |
| 五、利润总额 | 19,680,239.72 | 30,056,670.56 | 18,330,632.81 | 13,853,923.24 |
| 减:所得税费用 | 3,610,024.19 | -2,853,123.8 | -5,536,883.38 | -3,706,505.86 |
| 六、净利润 | 16,070,215.53 | 32,909,794.36 | 23,867,516.19 | 17,560,429.1 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 16,070,215.53 | 32,909,794.36 | 23,867,516.19 | 17,560,429.1 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 16,460,786.19 | 30,494,240.6 | 21,913,904.3 | 15,569,864.27 |
| 少数股东损益 | -390,570.66 | 2,415,553.76 | 1,953,611.89 | 1,990,564.83 |
| 扣除非经常损益后的净利润 | 13,708,421.47 | 19,204,404.82 | 14,981,173.93 | 11,988,298.74 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.04 | 0.08 | 0.06 | 0.04 |
| (二)稀释每股收益 | 0.04 | 0.08 | 0.06 | 0.04 |
| 八、其他综合收益 | -242,885.29 | -1,199,416.73 | -395,881.93 | -138,760.48 |
| 归属于母公司股东的其他综合收益 | -238,236.34 | -1,192,448.68 | -391,976.91 | -137,183.38 |
| 九、综合收益总额 | 15,827,330.24 | 31,710,377.63 | 23,471,634.26 | 17,421,668.62 |
| 归属于母公司股东的综合收益总额 | 16,222,549.85 | 29,301,791.92 | 21,521,927.39 | 15,432,680.89 |
| 归属于少数股东的综合收益总额 | -395,219.61 | 2,408,585.71 | 1,949,706.87 | 1,988,987.73 |
| 公告日期 | 2026-04-25 | 2026-04-25 | 2025-10-29 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |